AbbVie reports double-digit growth in 2015

AbbVie has announced its financial results for 2015, during which it delivered a revenue total of $22.82 billion (15.86 billion pounds).

This represented a year-on-year increase of 22.1 percent on an operational basis, while its adjusted earnings per share for the year came to $4.29, up 29.2 percent on 2014's figure.

Its strong performance was largely attributable to improved sales of its key product Humira, which saw a 16 percent operational sales increase in the fourth quarter of the year, while drugs such as Imbruvica, Viekira, Duodopa, Creon and Lupron also performed well.

The firm has announced diluted earnings per share guidance of $4.90 to $5.10 on an adjusted basis for 2016, which would represent continued double-digit growth and position AbbVie to be among the industry leaders for growth once again.

Richard Gonzalez, chairman and chief executive officer at AbbVie, said: "We achieved significant growth in 2015, and expect to continue building on that momentum in 2016 with another year of strong performance."

The company's total annual sales are forecast to reach around $37 billion by the end of the decade.